Purchase Summary

In order to access content on the FENIX Marketplace, you must have an account. You will also have access to FENIX Free updates.

The price for access is $599.00.

Account Information Already have an account? Log in here

LEAVE THIS BLANK

Welcome Email

By selecting this, I agree to receive emails from fenix.group.

You will be redirected to view the full article after purchasing. You will receive your account and payment information in a confirmation email, and can be viewed at any time in your Account.
RETURN TO HOME
$599
Glucose Monitoring, Topics

Abbott Q1 ’25 Earnings Update 

Here is a brief preview of this blast: Abbott hosted its Q1’25 earnings call (press release; infographic). Of note, there was minimal discussion of Abbott’s CGM business in prepared remarks and no questions from analysts during Q&A. Abbott’s CEO Rob Ford specifically stated, “I found it interesting we did not get a single Libre question, so you guys are very concerned on tariffs and macro...” Below, FENIX provides brief highlights and insights from the call.